JP2008535902A5 - - Google Patents

Download PDF

Info

Publication number
JP2008535902A5
JP2008535902A5 JP2008505964A JP2008505964A JP2008535902A5 JP 2008535902 A5 JP2008535902 A5 JP 2008535902A5 JP 2008505964 A JP2008505964 A JP 2008505964A JP 2008505964 A JP2008505964 A JP 2008505964A JP 2008535902 A5 JP2008535902 A5 JP 2008535902A5
Authority
JP
Japan
Prior art keywords
group
compound according
optionally substituted
treatment
attached
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008505964A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008535902A (ja
Filing date
Publication date
Priority claimed from GB0507831A external-priority patent/GB0507831D0/en
Application filed filed Critical
Priority claimed from PCT/GB2006/001369 external-priority patent/WO2006109081A1/en
Publication of JP2008535902A publication Critical patent/JP2008535902A/ja
Publication of JP2008535902A5 publication Critical patent/JP2008535902A5/ja
Pending legal-status Critical Current

Links

JP2008505964A 2005-04-15 2006-04-13 Dna−pk阻害剤 Pending JP2008535902A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US67183005P 2005-04-15 2005-04-15
US67188605P 2005-04-15 2005-04-15
GB0507831A GB0507831D0 (en) 2005-04-18 2005-04-18 DNA-PK inhibitors
US69606405P 2005-07-01 2005-07-01
US71890405P 2005-09-20 2005-09-20
PCT/GB2006/001369 WO2006109081A1 (en) 2005-04-15 2006-04-13 Dna-pk inhibitors

Publications (2)

Publication Number Publication Date
JP2008535902A JP2008535902A (ja) 2008-09-04
JP2008535902A5 true JP2008535902A5 (OSRAM) 2009-04-30

Family

ID=36579227

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008505964A Pending JP2008535902A (ja) 2005-04-15 2006-04-13 Dna−pk阻害剤
JP2008505966A Pending JP2008535903A (ja) 2005-04-15 2006-04-13 Dna−pk阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008505966A Pending JP2008535903A (ja) 2005-04-15 2006-04-13 Dna−pk阻害剤

Country Status (13)

Country Link
US (2) US20060264623A1 (OSRAM)
EP (2) EP1869040A1 (OSRAM)
JP (2) JP2008535902A (OSRAM)
KR (1) KR20080002963A (OSRAM)
AR (2) AR053358A1 (OSRAM)
AU (1) AU2006235731A1 (OSRAM)
CA (1) CA2603637A1 (OSRAM)
IL (1) IL186445A0 (OSRAM)
MX (1) MX2007012696A (OSRAM)
NO (1) NO20075809L (OSRAM)
TW (2) TW200720274A (OSRAM)
UY (1) UY29479A1 (OSRAM)
WO (2) WO2006109084A1 (OSRAM)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
ATE461193T1 (de) * 2003-08-13 2010-04-15 Kudos Pharm Ltd Aminopyrone und ihre verwendung als atm inhibitoren
TW200616986A (en) 2004-09-20 2006-06-01 Kudos Pharm Ltd DNA-pk inhibitors
JP2008529995A (ja) * 2005-02-09 2008-08-07 クドス ファーマシューティカルズ リミテッド Atm阻害剤
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
UY31232A1 (es) * 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones
EP2198710A1 (de) 2008-12-19 2010-06-23 Bayer CropScience AG Verwendung von 5-Pyridin-4yl-(1,3)Thiazole zur Bekämpfung phytopathogener Pilze
WO2010136778A1 (en) * 2009-05-29 2010-12-02 Kudos Pharmaceuticals Limited Dibenzothiophene derivatives as dna- pk inhibitors
JP5663571B2 (ja) 2009-07-02 2015-02-04 サノフイ 新規2,3−ジヒドロ−1H−イミダゾ{1,2−a}ピリミジン−5−オン誘導体、これらの調製およびこれらの薬学的使用
JP5680638B2 (ja) 2009-07-02 2015-03-04 サノフイ 新規な(6−オキソ−1,6−ジヒドロピリミジン−2−イル)アミド誘導体、この調製およびakt(pkb)リン酸化インヒビターとしてのこの医薬的な使用
RU2561130C2 (ru) 2009-07-02 2015-08-20 Санофи НОВЫЕ ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОПИРИМИДО{1,2-a}ПИРИМИДИН-6-ОНА, ИХ ПОЛУЧЕНИЕ И ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ
FR2947550B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
FR2947548B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 1h-pyrimidin-2-one, leur preparation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
JP5680639B2 (ja) * 2009-07-02 2015-03-04 サノフイ 新規6−モルホリン−4−イル−ピリミジン−4−(3h)−オン誘導体、およびakt(pkb)リン酸化阻害剤としてのこの医薬調製物
FR2947551B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a)pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
FR2951170B1 (fr) * 2009-10-09 2011-12-02 Sanofi Aventis Nouveaux derives de 1h-pyrimidin-2-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
US9618663B2 (en) 2010-04-15 2017-04-11 3M Innovative Properties Company Retroreflective articles including optically active areas and optically inactive areas
WO2011137428A1 (en) * 2010-04-30 2011-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating hiv infection: inhibition of dna dependent protein kinase
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
HUE024504T2 (en) 2010-12-23 2016-01-28 Sanofi Sa Pyrimidine derivatives, a process for their preparation and their use in medicine
EP2658844B1 (fr) 2010-12-28 2016-10-26 Sanofi Nouveaux derives de pyrimidines, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
US8530470B2 (en) * 2011-04-13 2013-09-10 Astrazeneca Ab Chromenone derivatives
MX371331B (es) 2012-04-24 2020-01-27 Vertex Pharma Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk).
ES2637829T3 (es) * 2012-06-15 2017-10-17 Basf Se Cristales multicomponentes que comprenden dasatinib y agentes de formación de cocristales seleccionados
FR2992316A1 (fr) 2012-06-22 2013-12-27 Sanofi Sa Derives de pyrimidinones, leur preparation et leur application en therapeutique
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
SI3527563T1 (sl) 2013-03-12 2022-01-31 Vertex Pharmaceuticals Incorporated Inhibitorji DNA-PK
US10287285B2 (en) * 2014-12-02 2019-05-14 Prana Biotechnology Limited 4H-pyrido[1,2-A]pyrimidin-4-one compounds
JP2019529475A (ja) 2016-09-27 2019-10-17 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Dna損傷剤とdna−pk阻害剤との組合せ物を使用する、がんを処置するための方法
CN109232476B (zh) * 2018-11-06 2020-06-26 常州大学 一种制备n-苯基-3-吗啡啉丙酰胺的方法
US20230111712A1 (en) * 2020-03-13 2023-04-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Stable reactive compositions for bioconjugation, probes, and protein labeling
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1303724A (OSRAM) 1969-05-14 1973-01-17
JPH0753725B2 (ja) * 1987-10-08 1995-06-07 富山化学工業株式会社 4h―1―ベンゾピラン―4―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
HUT58310A (en) 1988-12-21 1992-02-28 Upjohn Co Anti-atherosclerotic and anti-thrombotic 1-benzopyran-4-one- and 2-amino-1,3-benzoxazin-4-one derivatives, process for producing them and pharmaceutical compositions containing them
US5703075A (en) * 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
JPH03215423A (ja) 1990-01-18 1991-09-20 Kyowa Hakko Kogyo Co Ltd 血管拡張剤
ES2106783T3 (es) 1990-06-20 1997-11-16 Upjohn Co 1-benzopiran-4-onas y 2-amino-1,3-benzoxacin-4-onas antiarterosclerosis y antitromboticas.
WO1992000290A1 (en) 1990-06-29 1992-01-09 The Upjohn Company Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4h-pyran-4-ones
US5302613A (en) * 1990-06-29 1994-04-12 The Upjohn Company Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
US5252735A (en) * 1990-06-29 1993-10-12 The Upjohn Company Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
WO1994005283A1 (fr) 1992-09-02 1994-03-17 Kyowa Hakko Kogyo Co., Ltd. Medicament anti-vih
ATE203904T1 (de) * 1993-04-09 2001-08-15 Toyama Chemical Co Ltd Immunomodulator, zelladhäsionsinhibitor und mittel zur behandlung und vorbeugung von autoimmunerkrankungen
US5378725A (en) 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
US5504103A (en) 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5441947A (en) 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
US5468773A (en) 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
CA2133815A1 (en) 1993-10-12 1995-04-13 Jeffrey Alan Dodge Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof
US6632789B1 (en) 1994-04-29 2003-10-14 The United States Of America As Represented By The Secretary Of The Navy Methods for modulating T cell responses by manipulating intracellular signal transduction
US5480906A (en) 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
AU1461197A (en) 1995-11-16 1997-06-05 Icos Corporation Cell cycle checkpoint pik-related kinase materials and methods
GB2302021A (en) 1996-10-16 1997-01-08 Lilly Co Eli Inhibiting bone loss or resorption
WO1998055602A1 (en) 1997-06-06 1998-12-10 Mayo Foundation For Medical Education And Research Screening for phosphatidylinositol related-kinase inhibitors
AU8068198A (en) 1997-06-13 1998-12-30 President And Fellows Of Harvard College Methods for treating human cancers
FR2776291B1 (fr) 1998-03-18 2000-06-16 Pf Medicament Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
US6348311B1 (en) * 1999-02-10 2002-02-19 St. Jude Childre's Research Hospital ATM kinase modulation for screening and therapies
US6387640B1 (en) * 1999-02-10 2002-05-14 St. Jude Children's Research Hospital ATM kinase modulation for screening and therapies
US6333180B1 (en) * 1999-12-21 2001-12-25 International Flavors & Fragrances Inc. Bioprocess for the high-yield production of food flavor-acceptable jasmonic acid and methyl jasmonate
AU3042601A (en) * 2000-01-24 2001-07-31 Thrombogenix Pty Ltd Therapeutic morpholino-substituted compounds
KR20030017569A (ko) * 2000-06-28 2003-03-03 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
US7179912B2 (en) 2000-09-01 2007-02-20 Icos Corporation Materials and methods to potentiate cancer treatment
JP4458746B2 (ja) 2001-01-16 2010-04-28 グラクソ グループ リミテッド 癌の治療方法
GB0119863D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US6894055B2 (en) 2001-10-24 2005-05-17 Iconix Pharmaceuticals Inc. Thieno-2′,3′ -5,6pyrimido[3,4-A]-1,2,4-triazole derivatives as modulators of phoshoinositide 3-kinase
WO2003035618A2 (en) 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US7049313B2 (en) * 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
BR0307944A (pt) 2002-02-25 2005-02-01 Kudos Pharm Ltd Piranonas úteis como inibidores de atm
ES2357057T3 (es) * 2002-04-30 2011-04-15 Kudos Pharmaceuticals Limited Derivados de ftalazinona.
ATE461193T1 (de) * 2003-08-13 2010-04-15 Kudos Pharm Ltd Aminopyrone und ihre verwendung als atm inhibitoren
TW200616986A (en) * 2004-09-20 2006-06-01 Kudos Pharm Ltd DNA-pk inhibitors
JP2008529995A (ja) * 2005-02-09 2008-08-07 クドス ファーマシューティカルズ リミテッド Atm阻害剤
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
UY31232A1 (es) * 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones

Similar Documents

Publication Publication Date Title
JP2008535902A5 (OSRAM)
JP2008535903A5 (OSRAM)
ES2639064T3 (es) Derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1(2h)-ona sustituidos como inhibidores de cinasa
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
JP2011509949A5 (OSRAM)
JP2008001718A5 (OSRAM)
NZ700583A (en) Novel 7-deazapurine nucleosides for therapeutic uses
JP2008526999A5 (OSRAM)
JP2009541223A5 (OSRAM)
NO2016021I1 (no) 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2Hpyrido[2,3-D]pyrimidinderivater og relaterte forbindelser for behandling av kreft
JP2010504346A5 (OSRAM)
JP2014513704A5 (OSRAM)
JP2010241830A5 (OSRAM)
JP2009534408A5 (OSRAM)
JP2006519827A5 (OSRAM)
ATE437872T1 (de) Proteinkinaseinhibitoren
JP2006506443A5 (OSRAM)
RU2007110629A (ru) Ингибиторы днк-пк
JP2015512943A5 (OSRAM)
RU2011133128A (ru) Противоопухолевые соединения дигидропиран-2-она
JP2015500884A5 (OSRAM)
EA200800516A1 (ru) Производные n-фенил-2-пиримидинамина и процесс их получения
JP2015502371A5 (OSRAM)
MX2007013624A (es) Inhibidores de proteina cinasa.
AR045811A1 (es) 5- arilpirimidinas como agentes ainticancerigenos